I identify where promising longevity interventions are likely to fail when translated to human outcomes.
Short-form assessments of where promising interventions break under translation.
1) IL-11 inhibition
Strong preclinical effects on metabolic health and lifespan in mice suggest broad anti-aging potential.
Likely failure point: effects are partly mediated through mechanisms less relevant in humans (e.g. brown adipose tissue activity and species-specific metabolic differences).
Implication: magnitude of benefit is likely to attenuate in humans despite strong animal data.2) Mesenchymal stem cells (MSCs)
Attractive due to regenerative signaling and immunomodulatory effects in vitro and in animal models.
Likely failure point: poor engraftment and persistence in human tissues—effects are transient and largely paracrine.
Implication: sustained functional improvements are unlikely without solving integration, even with repeated dosing.3) Hyperbaric oxygen therapy (HBOT)
Reported to improve biomarkers such as telomere length and senescent cell burden.
Likely failure point: biomarker shifts may reflect changes in cell population dynamics (e.g. immune cell redistribution) rather than reversal of underlying damage.
Implication: measured improvements may not translate into durable effects on aging or function.
More detailed analyses are available in selected writing below.
I work with investors, founders, and operators to evaluate longevity interventions and claims when evidence is incomplete and superficial analysis is likely to mislead.
Most useful when: a decision requires committing attention, capital, or credibility before the evidence is conclusive.
I focus on questions where the core issue is not information, but judgment: whether a claim or intervention is actually decision-relevant.
Specifically:
• whether a mechanism is likely to survive translation to organism-level outcomes
• where promising interventions are likely to fail
• distinguishing signal from narrative in early data.
• investors assessing longevity-related opportunities or claims
• founders and operators working on interventions or platforms
• physicians or scientifically sophisticated individuals evaluating contested approaches
• researchers or organizations that need clear mechanistic judgment rather than optimistic interpretation
Most useful when the question is not whether something is interesting, but whether it is likely to matter.
This includes situations where a mechanism appears compelling but translation is unclear, where early data has generated disproportionate confidence, or where a decision requires a sharper external view before committing attention, capital, or credibility.
I have studied aging biology for more than 20 years and have worked professionally as an independent analyst since 2011, producing detailed evaluations of interventions, mechanisms, and emerging claims for private clients and ongoing research.
These pieces are examples of how I reason.
• Why Aging Is Not Fundamentally Programmed
→ examines where programmed aging models fail mechanistically and why they do not translate into organism-level aging
• How I Evaluate Longevity Interventions
→ outlines the framework for evaluating longevity interventions, illustrated with concrete examplesMore writing on Substack
I am selectively available for a limited number of serious engagements and conversations.
Most work begins with a specific question or decision context.
Email: [email protected]
• LinkedIn
• Substack